Jump to ContentJump to Main Navigation

Online

149,00 € / $224.00*

* Prices subject to change. Shipping costs will be added if applicable.
Publication Date:
January 2010
ISSN:
2191-0251
DOI:
10.1515/jpem.2010.160

See all formats and pricing

Online
Individual Subscription Online only
Euro [D] 149.00
RRP for USA, Canada, Mexico
US$ 224.00 *
Print
Individual Subscription Online only
Euro [D] 873.00
RRP for USA, Canada, Mexico
US$ 1310.00 *
Print + Online
Individual Subscription Online only
Euro [D] 1048.00
RRP for USA, Canada, Mexico
US$ 1572.00 *
*Prices subject to change. Shipping costs will be added if applicable.

Editor-in-Chief: Zadik, Zvi

Editorial Board Member: Cassorla, Fernando / Cutfield, Wayne / de Muinck Keizer-Schrama, Sabine M.P.F. / Fideleff, Hugo L. / LaFranch, Stephen H. / Lanes M. D., Roberto / Levitsky, Lynne / Lippe, Barbara / Pfäffle, Roland / Root, Allen W. / Rosenfeld, Ron G. / Werther, George / Kiess, Wieland

12 Issues per year

IMPACT FACTOR 2011: 0.875
5-year IMPACT FACTOR: 1.026

VolumeIssuePage

Issues

Evaluation and Follow-up of Clinically Euthyroid Children with Normal Free T4 and Suppressed TSH

Priya Vaidyanathan1 / Paul B. Kaplowitz1

1Department of Endocrinology, Children's National Medical Center, Washington, DC, USA

c1Corresponding author: Priya Vaidyanathan, MD,

Citation Information: Journal of Pediatric Endocrinology and Metabolism. Volume 23, Issue 10, Pages 993–997, ISSN (Online) 2191-0251, ISSN (Print) 0334-018X, DOI: 10.1515/jpem.2010.160, January 2010

ABSTRACT

Aim: Although subnormal TSH between 0.1-0.4 mIU/L is fairly common and benign, suppression of TSH to < 0.1mIU/L with normal free T4 is less common and more worrisome. We have conducted a retrospective chart review of a collection of such cases and have summarized the features and outcome on follow up.

Methods: We studied 23 consecutive patients referred from 2005-07 to our pediatric endocrine clinic with TSH < 0.1 mIU/L and free T4 in the range of 0.8-2 ng/dl. We collected historical, clinical and laboratory data, and analyzed their outcome.

Results: The natural evolutions of these subjects were separated into 4 groups. Group 1, 14 subjects, (61%) became euthyroid within a mean of 3.7 months. Group 2, 4 subjects, (17%) became hypothyroid within a mean of 2.8 months. Group 3, 2 subjects (9%) progressed to overt hyperthyroidism. Group 4, 3 subjects (13%) had persistently suppressed TSH, 8-14 months after initial testing, of which one had a multinodular goiter and had a thyroidectomy. Elevated thyroid peroxidase antibody (TPO) was seen in 54.5% of those tested.

Conclusion: Only 2/23 in our series became overtly hyperthyroid. Substantial number of subjects had a short period of transient TSH suppression that resolved spontaneously. Markers suggestive of autoimmune thyroid disease were consistently seen in group 2 and less so in others. It is prudent to observe such cases in the short term with serial follow up TSH, free T4 and T3, and to reserve further testing and treatment for those who become symptomatic or do not resolve.

Comments (0)

Please log in or register to comment.